



Targeted Cancer Therapy With No Side Effects
BIOLOGICAL DRUG FOR PANCREATIC CANCER



Management Team

JELLYFISH



Team of Accomplished Scientists and Entrepreneurs



Avigail Osnat Anavi
BA Pharmacy
CEO FOUNDER OWNER

CEO
Founder & Owner of
AGAVI Group
· Chief Pharmacist



Prof.
Reuven OR, MD
Chief Scientific officer

Chief Radiologist at MEUHEDE
Former Head of NBC Medical
Treatment Department at the
IDF Medical Corps



DR. Tawanda
Gumbo MD

Chief Scientific Advisor
· Lecturer in the Department of
Maritime Civilizations
· Marine Ecology Consultant for
Various Companies



DR. Tzvika
Dushnitsky, CTO
MD, MBA, MAH

· Associate Professor of Medicine,
The Hebrew University of
Jerusalem
· Director of the Cancer
Immunotherapy and
Immunobiology Research Center

The revenue we expect from the moment the product is launched for 15 years.

- **Sales forecast –**
- **Our market**

- shares out of the overall market of pancreatic and liver cancer drugs.
- The market share is expected to be 12% of the total market
- As a model, I took Herceptin, a biological drug for breast cancer, sales of Herceptin stood at \$204 million, grew to \$411 million in 2019, \$636 million in 2020, and \$803 million in 2021, with Teva's forecast sales of \$1 billion for 2022
- The price of Herceptin is -13000 NIS
- Net profit is expected to be about \$10 billion
-
- **The business model** – is reaching the FDA approval stage selling to a pharmaceutical company

-
- **Milestones for a period of 3 years-**

- Fractionation of the venom and its finding of an active substance
- An experiment on cancer cells to verify its activity
- Experiment on mice with liver and pancreatic cancer
- Preparation of the study for IND's CHIP
-

AVIMEDUZA overview

JELLYFISH



AVIMEDUZA is focused on safe and effective cancer treatments without the side effects associated with chemotherapy

Founded in **2022**

HQ-Jerusalem, Israel

Employees- 3+

IP-Patent -Solution is protected through United States Provisional Patent Application **No. 63/487,018** filed on February 27,

2023

Effective Against Liver, lung, breast, pancreatic Cancer Cells.



Liver and Pancreatic Cancer Diseases

Liver and Pancreatic Cancers are Difficult to Treat With Low Survival Rates



Disease

Liver and Pancreatic cancers are some of the most difficult to detect early and their nature




Therapy



No good treatment exists for both liver and pancreatic cancers, but chemotherapy.

In response to the usual late-stage diagnosis, aggressive chemotherapy has deleterious side effects on the cancer patients leading to low survival rates.

A therapy that kills cancer cells without damaging nearby healthy tissue is ideal




Capital Requirements

FOR AVIMEDUZA-JELLYFISH



Capital funding required for the preclinical development for the jellyfish venom toxin peptide up to IND


Focus Areas for Investment	Funding Amount Required
Early R&D for formulation -seed	500 K
R&D and Preclinical Studies data IND	4,450.000
Governance and Intellectual Property	75,000
Team Salaries,Overhead,and Working Capital	200,000
Transaction Expenses	275,000
Total Required Investment	 5,500,000\$

Liver and Pancreatic Cancer Impact Millions Across the Globe

While Pancreatic Cancer is More Prevalent in North America and Europe, Liver Cancer is More Common in Asia and Africa



1,500,000 new people are diagnosed with liver and pancreatic cancer per year 15% of all cancer cases



Total Addressable Market

1.5M New Cases of Liver and Pancreatic Cancer Per Year @\$35,000 per Treatment



500 K

Number of New Cases of Pancreatic Cancer Diagnosed Per Year




1,000K

Number of New Cases of Liver Cancer Diagnosed Per Year




USD 51.5Bn

Overall Estimated Total Addressable Market



AVIMEDUZA Technology Differentiation for advanced liver cancer



AVIM001 Targets Cancer Cells Without Damaging Healthy Cells and Causing Side Effects

MARKET LEADERS/STANDARD OF CARE

Ablation therapy

Embolization therapy

✓ Bevacizumab (antibody)

✓ cabozantinib

✓ lenvatinib

✓ Ramucirumab (antibody)

✓ regorafenib

Sorafenib

✓ olmmune checkpoint inhibitors

atezolizumab with the targeted therapy

ALL HAVE A LOT OF SIDE EFFECT

AVIMEDUZA Technology

In the Avimeduza treatment we will use the active part jellyfish venom that will be given by infusion to the cancerous tumor in the liver and pancreas. The treatment is targeted and does not harm the healthy cells and will save severe side effects and weakening of the body



A New Drug Development Approach Proven with the FDA

Proprietary Platform Delivers More Affordable Therapeutics to the Market Faster
Drug Development Stages at Praedicare Mirror the FDA Target Product Profile for Pre-IND



FDA Criteria	FDA Target Profile for Pre-IND and IND	Praedicare Stages
Indication	Defined :Localized and metastatic liver cancer Defined :Localized and metastatic pancreatic cancer	
Population	Impact: 1.5 million patients per year globally	
Clinical Efficiency	Archieve 3x the 5-yr survival rate on current therapies - liver cancer has 21%survival rate(target =63%) -pancreatic cancer has 18%survival rate(target =54%)	Establish 3x higher extinction rates of 3D cancer cell populations than standard of care in Praedicare preclinical models translated to patients
Safety &Tolerability	90%fewer adverse events compared to chemotherapy and immune checkpoint inhibitors	Safe doses are identified using Praedicare's preclinical models,AI, and quantitative forecasting
Stability	Stable for 1 year at room temperature	Pharmaceutical Chemistry,Manufacturing & Controls at Praedicare
Route to Administration	Intravenous:targeted vehicles carrying drug to liver and pancreatic cancer cells,including metastasis Hepatic arterial infusion	Hollow Fiber System at Praedicare
Dosing Frequency	Once every 2 weeks	Derived from PK/PD data package at Praedicare
Time to Availability	3 years	1 year at Praedicare

The results of vitro study on cancer cells



The results of vitro study in Hadassa Hospital cancer cells


The research conclusion:

Jellyfish treatment have toxic effect on tumor cells,

The venom has an effects on the enzyme of the cancer cell that caused its death

and therefore, can be further investigated to develop a cancer therapy

The results of vitro study on healthy cells



Results:

Cell viability was preserved in the presence of extract.

At the highest concentration cell viability was compared to the control.

Conclusion:

21.2.24

Jellyfish treatment is not toxic to non-cancerous **HaCaT** cells and therefore can be further investigated to develop a cancer therapy.

Scope of Collaboration with Praedicare



R&D, Preclinical and Clinical Development, IND and Phase I and Phase II Designs
(\$4.95M upfront plus milestone payments post IND, Phase I, and Phase II)

01

Research & Development

- Isolate Active Ingredient in Jellyfish Venom
- Characterize, Purify, and Manufacture Sufficient Quantities
- Develop Delivery System for Targeting Cancer Cells

03

Phase I/II Designs

Based on the preclinical studies results Praedicare will design streamlined Phase I and Phase II designs that use fewer patients that will save drug development costs



02

Preclinical Studies to IND

- Efficacy and Toxicity Studies Using Hollow Fiber System
- Translation of Preclinical Data Readouts and Quantitative Forecasting to the Clinic
- PK/PD Package for IND

04

Post Phase III

- Royalties

Contact Us



|||||||

|||||||

|||

|||

!!

Address:

AVIMEDUZA JELLYFISH LTD.
Bait Vegan 99,
Jerusalem 9642612,Israel,
www.agavigroup.com



Contact Numbers:

Avigail Osnat Anavi,Founder
+97254-468-5209

M.Johnson Kachidza,Advisor
+1(489)849-3919



Email Address:

Avigail Osnat Anavi,Founder
osnatavigyl@gmail.com



M.Johnson Kachidza,Advisor
johnson@praedicareinc.com